A novel translational pipeline for the treatment of multiple myeloma
Dr. Indryas Woldie
Windsor Regional Hospital
FUNDER: Windsor Cancer Centre Foundation (WCCF)
DURATION: 2023-2024
There are several lines of therapy available for Multiple Myeloma (MM) patients, but over time, most patients develop resistance to the available standard of care. Several medications have been approved for these refractory patients; however, response is usually short lived, and patients eventually succumb to the disease. Putting patient tissues into mice is a common model used for testing new drugs and exploring the biology of other forms of cancer, however, for patient MM samples, they are notoriously difficult to work with outside of the body and there is a lack of xenograft mouse models. By refining the zebrafish model that is acting as a xenograft system, novel therapies for MM patients can be screened and used to test personalized medicine approaches.
For refractory MM patients at Windsor Regional Hospital and other locations, this treatment of targeting Cdks may offer exceptional benefits when no more effective therapy is available. This project will also establish an innovative screening platform that will stratify MM patients for a promising avenue of treatment, and lead to advancement in personalized medicine.
